“Because of great work, two prizes went to the same person,” Prof. Axel Merseburger (DE) said in his introduction of Dr. Ekaterina Laukhtina (AT). She managed to earn two Best Poster Awards, in the categories of “Renal Cell Cancer, Testicular Cancer & Penile Cancer” and “Urothelial Cancer.”

“Adjuvant immunotherapy versus tyrosine kinase inhibitors in patients with high-risk renal cell carcinoma: A systematic review and network meta-analysis of oncologic and toxicity outcomes” was the study that won Dr. Laukhtina and her team the Best Poster Award – Renal Cell Cancer, Testicular Cancer & Penile Cancer. “The superior oncologic benefit of pembrolizumab together with its better toxicity profile support it as the new standard of care in the adjuvant setting for nephrectomy patients at high risk of renal cell carcinoma relapse,” Dr. Laukhtina said.

Preoperative plasma level of endoglin
The Best Poster Award – Urothelial Cancer that Dr. Laukhtina received was for the study “Preoperative plasma level of endoglin as a predictor for disease outcomes after radical cystectomy for non-metastatic urothelial carcinoma of the bladder,” she and her team conducted. About this research, she said, “Preoperative plasma endoglin is associated with features of biologically and clinically aggressive urinary bladder urothelial carcinoma (UCB) as well as survival outcomes. Preoperative plasma endoglin seems to hold the potential of identifying UCB patients who may benefit from an intensified therapy in addition to radical cystectomy such as an extended lymphadenectomy or/and preoperative systemic therapy.”

Unfortunately, Dr. Laukhtina was unable to attend the session in person.

Cisplatin or carboplatin
Dr. Anke Richters (NL) also received a Best Poster Award – Urothelial Cancer for her and her team’s study “Overall survival of patients receiving cisplatin or carboplatin for primary metastatic urothelial carcinoma of the bladder: A contemporary Dutch nationwide cohort study” (see photo above). About the results of the study, Dr. Richters said:

“Metastatic urothelial carcinoma (mUC) patients receiving cisplatin or carboplatin differ on prognostic factors. Balance can be achieved through an inverse probability of treatment weighting. The overall survival benefit of cisplatin after 24 months was estimated at 2 months but was not significant. The survival benefit should be weighed against toxicity levels.”

Read the award-winning abstracts and their posters in the EMUC21 Resource Centre! Here, EMUC21 delegates can access all presentations, full-text abstracts, and (e-)posters.

The post Another EMUC21 day, another round of best poster award winners appeared first on EMUC25.

“Compared to last year in Barcelona where we received and reviewed around 178 abstracts, this year saw an increase in submissions to both the EMUC and the annual meeting of the EAU Section of Urological Imaging (ESUI),” the organisers said.

Included in the 237 submissions were 27 abstracts submitted for the ESUI. Last year the ESUI reviewed a lower number of abstracts at 15 submissions. EMUC received in 2015 for the seventh meeting around 178 submissions including six contributions for the oral sessions.

This year the deadline for late-breaking abstracts is August 30. Interested contributors for late-breaking abstracts are required to submit high quality, new research findings with implications for clinical practice. The organisers will only accept proposed late breaking abstracts whose outcomes or findings were not available at the time of the 1 July deadline.

All submissions will undergo review and screening and authors of accepted abstracts will be notified of the results by next month.

Abstracts with innovative insights and perspectives will also be highlighted and commended during the meeting, while ESUI will grant a cash reward to the authors of the best abstract during its meeting on 24 November.

The post Higher abstract submission record for EMUC16 appeared first on EMUC25.